Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma.

Ayala-Ramirez M, Palmer JL, Hofmann MC, de la Cruz M, Moon BS, Waguespack SG, Habra MA, Jimenez C.

J Clin Endocrinol Metab. 2013 Apr;98(4):1492-7. doi: 10.1210/jc.2012-4231. Epub 2013 Feb 22.

2.

Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma.

Xu JY, Murphy WA Jr, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI.

J Clin Endocrinol Metab. 2016 Dec;101(12):4871-4877. Epub 2016 Sep 23.

3.

Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.

Hamidi O, Young WF Jr, Iñiguez-Ariza NM, Kittah NE, Gruber L, Bancos C, Tamhane S, Bancos I.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3296-3305. doi: 10.1210/jc.2017-00992.

PMID:
28605453
4.

Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark.

Jensen AØ, Jacobsen JB, Nørgaard M, Yong M, Fryzek JP, Sørensen HT.

BMC Cancer. 2011 Jan 24;11:29. doi: 10.1186/1471-2407-11-29.

5.

Short-term disability in solid tumor patients with bone metastases and skeletal-related events.

Qian Y, Song X, Zhang K, Balakumaran A, Arellano J.

J Med Econ. 2015 Mar;18(3):210-8. doi: 10.3111/13696998.2014.975232. Epub 2014 Dec 11.

PMID:
25426582
6.

The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.

Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G.

Oncology. 2004;67(5-6):390-6.

PMID:
15713995
7.

Skeletal-related events due to bone metastases from differentiated thyroid cancer.

Farooki A, Leung V, Tala H, Tuttle RM.

J Clin Endocrinol Metab. 2012 Jul;97(7):2433-9. doi: 10.1210/jc.2012-1169. Epub 2012 May 7.

PMID:
22564664
8.

Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.

Ding X, Fan Y, Ma F, Li Q, Wang J, Zhang P, Yuan P, Xu B.

Breast. 2012 Aug;21(4):544-9. doi: 10.1016/j.breast.2012.04.008. Epub 2012 May 22.

PMID:
22627092
9.

Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.

Klaassen Z, Howard LE, de Hoedt A, Amling CL, Aronson WJ, Cooperberg MR, Kane CJ, Terris MK, Freedland SJ.

Cancer. 2017 May 1;123(9):1528-1535. doi: 10.1002/cncr.30505. Epub 2016 Dec 27.

PMID:
28026865
10.

The economic burden of skeletal-related events among elderly men with metastatic prostate cancer.

Jayasekera J, Onukwugha E, Bikov K, Mullins CD, Seal B, Hussain A.

Pharmacoeconomics. 2014 Feb;32(2):173-91. doi: 10.1007/s40273-013-0121-y.

PMID:
24435407
11.

Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.

Ulas A, Bilici A, Durnali A, Tokluoglu S, Akinci S, Silay K, Oksuzoglu B, Alkis N.

Tumour Biol. 2016 Jan;37(1):1131-40. doi: 10.1007/s13277-015-3907-z. Epub 2015 Aug 15.

PMID:
26276360
12.

Skeletal-related events and prognosis in urothelial cancer patients with bone metastasis.

Tsuda Y, Nakagawa T, Shinoda Y, Kanatani A, Kawai T, Taguchi S, Yamada Y, Sawada R, Kume H, Homma Y, Tanaka S, Kawano H.

Int J Clin Oncol. 2017 Jun;22(3):548-553. doi: 10.1007/s10147-016-1075-9. Epub 2017 Jan 2.

PMID:
28044212
13.

Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.

Katakami N, Kunikane H, Takeda K, Takayama K, Sawa T, Saito H, Harada M, Yokota S, Ando K, Saito Y, Yokota I, Ohashi Y, Eguchi K.

J Thorac Oncol. 2014 Feb;9(2):231-8. doi: 10.1097/JTO.0000000000000051.

14.

Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.

Murphy L, McCarthy J, McCrate F, Laing K, Powell E, Seal M, Edwards S.

Support Care Cancer. 2013 Jun;21(6):1557-60. doi: 10.1007/s00520-012-1694-2. Epub 2013 Jan 19.

PMID:
23334521
15.

The incidence and clinical impact of bone metastases in non-small cell lung cancer.

Kuchuk M, Kuchuk I, Sabri E, Hutton B, Clemons M, Wheatley-Price P.

Lung Cancer. 2015 Aug;89(2):197-202. doi: 10.1016/j.lungcan.2015.04.007. Epub 2015 May 11.

PMID:
26003503
16.

Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases.

Hagiwara M, Delea TE, Chung K.

J Med Econ. 2014 Mar;17(3):223-30. doi: 10.3111/13696998.2014.890937.

PMID:
24494707
17.

Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.

Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, Busaidy N, Cote GJ, Perrier N, Phan A, Patel S, Waguespack S, Jimenez C.

J Clin Endocrinol Metab. 2011 Mar;96(3):717-25. doi: 10.1210/jc.2010-1946. Epub 2010 Dec 29.

PMID:
21190975
18.

Canadian health care institution resource utilization resulting from skeletal-related events.

Habib MJ, Merali T, Mills A, Uon V.

Hosp Pract (1995). 2014 Feb;42(1):15-22. doi: 10.3810/hp.2014.02.1087.

PMID:
24566592
19.

Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis.

Hussain A, Aly A, Daniel Mullins C, Qian Y, Arellano J, Onukwugha E.

Cancer Med. 2016 Nov;5(11):3300-3309. doi: 10.1002/cam4.914. Epub 2016 Oct 11.

Supplemental Content

Support Center